Comments
Pfizer Inc has filed a petition in a US court against Aurobindo Pharma Ltd and Dr Reddy’s Laboratories Ltd on their alleged separate plans to launch generic versions of its drug Ibrance (palbociclib) before expiration of its patent.
The drug is indicated in the treatment of certain types of cancer. It clocked about $5 billion revenue in globally for Pfizer, according to agency reports citing company data.
The companies assert the invalidity and non-infringement of two composition-of-matter patents and a method-of-use patent covering palbociclib, each of which expires in 2023, according to the annual report.
Pfizer contented that the Hyderabad-based drug makers had filed abbreviated new drug application (ANDA) with the US drug regulator for approval for the generic of Ibrance prior to the expiry of the patent.
When contacted, Dr Reddy's Laboratories declined to comment. Aurobindo, too, has not come out with a statement on the matter yet.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.